Joint Transnational Call (JTC2016)

These projects were funded under E-Rare.

Factsheet (PDF)

General information
Topic: Clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases
Budget: 11 milion €
Funded projects: 8
The following parties have decided to open the eighth E-Rare joint transnational call (JTC 2016) for funding multilateral clinical research projects on rare diseases:
•    Austrian Research Promotion Agency (FFG), Austria
•    Fonds zur Förderung der Wissenschaftlichen Forschung (FWF), Austria
•    Research Foundation – Flanders (FWO), Belgium (Flanders)
•    Canadian Institutes of Health Research (CIHR), Canada
•    Fonds de recherche du Québec – Santé (FRQS), Canada, Québec
•    French National Research Agency (ANR), France
•    Ministère des Affaires sociales, de la Santé et des Droits des femmes (DGOS), France
•    German Federal Ministry of Education and Research (BMBF), Germany
•    German Research Foundation (DFG), Germany
•    National Research, Development and Innovation Office (NKFIH), Hungary
•    Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
•    Italian Ministry of Health (MoH), Italy
•    State Education Development Agency (Valsts izglītības attīstības aģentūra VIAA), Latvia
•    Narodowe Centrum Badań i Rozwoju (NCBR), Poland
•    Foundation for Science and Technology (FCT), Portugal
•    Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
•    National Institute of Health Carlos III (ISCIII), Spain
•    Swiss National Science Foundation  (SNSF), Switzerland
•    The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey

  • ReDox: Repurposing doxycycline in the treatment of AL amyloidosis
  • NICOFA: Nicotinamide for the treatment of Friedreich ataxia
  • DPem: Dimethylfumarate for the treatment of bullous pemphigoid
  • HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD
  • ROPROP: Propranolol for preemptive treatment of threshold retinopathy of prematurity
  • ROCK-ALS: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
  • REALS: Repurposed Enoxacin for the treatment of patients with Amyotrophic Lateral Sclerosis
  • TAMDMD: Tamoxifen in Duchenne muscular dystrophy – a randomised placebo controlled phase 2 trial